ホーム › 急性骨髄性白血病 › ミシガン州 › Ann Arbor
Ann Arbor、MIにおける急性骨髄性白血病の臨床試験
Ann Arborとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18マイル先
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- 他4件
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18マイル先
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti · 7マイル先
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
- 他1件
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
被験者募集中第1相
- C S Mott Children's Hospital, Ann Arbor
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18マイル先
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18マイル先
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7マイル先
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15マイル先
- 他1件
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- C S Mott Children's Hospital, Ann Arbor
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
被験者募集中第3相
- C S Mott Children's Hospital, Ann Arbor
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- C S Mott Children's Hospital, Ann Arbor
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- C.S. Mott Children's Hospital, Ann Arbor
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- University of Michigan, Ann Arbor
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- University of Michigan, Ann Arbor
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1相
- University of Michigan, Ann Arbor
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- University of Michigan Comprehensive Cancer Center, Ann Arbor
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Baldwin Park, CA40件の研究
- Seattle, WA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA30件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Ann Arborにおける他の研究
- 前立腺がん27件の研究
- 乳がん26件の研究
- 非小細胞肺癌26件の研究
- がん（全種類）25件の研究
- 大腸癌23件の研究
- 肺がん23件の研究
- 心不全22件の研究
- 心血管疾患16件の研究
- 膵臓がん14件の研究
- 悪性黒色腫12件の研究
- 腎臓がん（腎細胞がん）12件の研究
- 頭頸部扁平上皮癌12件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。